A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder
J Biederman, RD Melmed, A Patel, K McBurnett… - …, 2008 - publications.aap.org
OBJECTIVE. With this study we assessed the efficacy and safety of an extended-release
formulation of guanfacine compared with placebo for the treatment of children and
adolescents with attention-deficit/hyperactivity disorder. METHODS. In this multicenter,
double-blind, placebo-controlled, fixed-dosage escalation study, patients aged 6 to 17 years
were randomly assigned to 1 of 3 treatment groups of guanfacine extended release (2, 3, or
4 mg/day) or placebo for 8 weeks. The primary outcome measurement was the Attention …
formulation of guanfacine compared with placebo for the treatment of children and
adolescents with attention-deficit/hyperactivity disorder. METHODS. In this multicenter,
double-blind, placebo-controlled, fixed-dosage escalation study, patients aged 6 to 17 years
were randomly assigned to 1 of 3 treatment groups of guanfacine extended release (2, 3, or
4 mg/day) or placebo for 8 weeks. The primary outcome measurement was the Attention …
Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder
FR Sallee, A Lyne, T Wigal… - Journal of child and …, 2009 - liebertpub.com
Objective: Short-term, controlled studies of extended-release guanfacine (GXR), a selective
α2A-adrenoreceptor agonist, demonstrate efficacy in treating attention-deficit/hyperactivity
disorder (ADHD) symptoms as monotherapy. This 2-year open-label study was conducted to
further assess the long-term safety and efficacy of GXR. Methods: Study participants, aged 6–
17 years with ADHD, had previously been exposed to GXR therapy alone or in combination
with psychostimulants in one of two antecedent trials. In this study, doses were titrated to 1 …
α2A-adrenoreceptor agonist, demonstrate efficacy in treating attention-deficit/hyperactivity
disorder (ADHD) symptoms as monotherapy. This 2-year open-label study was conducted to
further assess the long-term safety and efficacy of GXR. Methods: Study participants, aged 6–
17 years with ADHD, had previously been exposed to GXR therapy alone or in combination
with psychostimulants in one of two antecedent trials. In this study, doses were titrated to 1 …